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Abstract- Glucocorticoid steroids are widely used as anti-inflammatory and immunosuppressive 
medications and are well known to induce osteoporosis. In Present study 24 rats were randomly divided into 
four groups (n=6): Group A (control), Group B (sham)that was treated only by normal saline  for 1 
month.Group C that was treated by methylprednisolone acetate alone (0.2 mg/kg) for 1 month. Group D that 
was treated by methylprednisolone acetate (0.2 mg/kg) and oral calcium supplementation (15 mg/kg) for 1 
month. Changes in concentration of bone metabolic markers such as osteocalcine, acid phosphatase and 
calcium were evaluated before and after treatment. Bone mineral density (BMD) of lumbar vertebrae was also 
measured by dual energy X ray absorptiometry (DEXA). The results showed that concentration mean of 
serum acid phosphatase was increased significantly (P < 0.05) in C and D groups in compared to A and B 
groups. The concentration mean of serum osteocalcine in group C was decreased significantly (P < 0.05) in 
comparison to A and B groups but increased significantly in the group D in comparison to group C. The 
concentration mean of serum calcium was decreased significantly (P < 0.05) in C and D groups in compared 
to A and B groups. The bone mineral density (g/cm2) was decreased significantly (P < 0.05) in group C in 
compared to A and B groups. This increased significantly in group D in compared to group C. These results 
are compatible with the view that low doses of methylprednisolone acetate decreases bone formation and 
increase bone resorption in the lumbar vertebrae of rats. Calcium administration decreased effects of 
methylprednisolone. 
© 2009 Tehran University of Medical Sciences. All rights reserved. 
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Osteoporosis is a major complication in patients who 
require chronic glucocorticoid treatment (1). The 
glucocorticoid-induced bone loss mainly results from 
depressed osteoblastic activity and differentiation, but 
many pathways contribute to the skeletal morbidity: 
enhanced osteoclastic activity, reduced intestinal 
calcium absorption, increased renal calcium excretion, 
disturbances in vitamin D and gonadal hormones 
metabolism and increased apoptosis of osteoblasts and 
osteocytes (2-5). The lumbar spine and proximal part of 
femur are particularly vulnerable to osteoporosis and 
related fractures caused by glucocorticodis (6). The bone 
density, which defines the degree of osteoporosis and 
the fracture risk, is generally determined by dual-energy 
X-ray absorptiometry (DEXA) (7). The main 
determinants of peak bone density are genetic, but there 
is some evidence that calcium intake and exercise also 
make a contribution (8). In addition there is surprisingly 
weak evidence on which to support clear 
recommendations about low doses of glucocorticois (< 
10 mg prednisolone equivalent per day) are essential for 
normal osteoblasts function, inducing osteoblasts 
differentiation by increased expression of mature bone 
markers, such as alkaline phosphatase and osteocalcine 
(9). Osteoporosis is largely preventable due to advances 
in our understanding of its causes and the availability of 
effective therapeutic interventions (10). Prevention of 
osteoporosis should be considered even when the 
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glucocorticoid dose is intermittent or low (prednisolone 
< 5 mg/d or equivalent) (11). Optimal prevention and 
treatment of osteoporosis requires supplementation with 
calcium and vitamin D, particularly if dietary intake is in 
adequate (7). Most patients require calcium 
supplementation to meet the recommended daily intake 
of 1000 to 1500 mg/d (7, 11) and those at risk also may 
require vitamin D supplements (800 IU/d) (11). 
Although calcium and vitamin D and its derivatives 
have only weak antiresorptive effects compared with 
other pharmacological agents deficiency of either will 
compromise bone strength (12). However, there are 
discrepancies in the results of in vivo studies in man and 
animals. While high doses or long-term glucocorticoid 
therapy cause bone resorption and decrease bone 
mineral density (13, 14) other studies demonstrated that 
low-dose treatment increased bone formation (15, 16). 
Whether administration of low-dose glucocorticoids can 
decrease bone loss in glucocorticoids users has not been 
convincingly demonstrated so far (17). The present 
study was designed to evaluate the prevention effect of 
bone loss with calcium as an anti-resorptive agent in 
methylprednisolone acetate induced osteoprosis as a 
member of glucocorticoid family by using biochemical 
markers (calcium, osteocalcine, acid phosphatase) and 
Bone Mineral Density (BMD) in rat model. 
 
Patients and Methods 
 
In Present studies 24 male Sprague-Dawley rats (180-
200gr) were purchased from Pasteur Institute (Iran). The 
rats were housed in cages in a controlled atmosphere 
room (temperature 24oc, 12 h light: dark cycle). The 
animals fed from a standard rat chow containing 0.75 % 
calcium, 0.6 % phosphorus, 500 IU/kg vitamin D3 (pars 
animals food) and tab water. They were kept on this diet 
through the study. Twenty four rats were randomly 
divided into four groups (n = 6). Group A, was a base 
line control or normal animal. Group B (sham), treated 
only by normal saline (0.9 %, 100 micro liter/100 gr. 
Body weight) injection subcutaneously (3 times weeks 
for 1 month). Group C, treated by methylprednisolone 
acetate alone (0.2 mg/kg) subcutaneously injection (3 
times/week for 1 month). Group D, treated by 
methylprednisolone acetate (0.2 mg/kg) subcutaneously 
injection (3 times/week for 1 month) and 15 mg/kg oral 
calcium supplementation for 1 month.  
 
Determination of bone metabolic markers 
In order to assess bone metabolic markers, blood was 
drawn by puncturing of orbital sinus before and after 
performed the protocol under diethyl/ether anesthesia. 
The blood samples were immediately centrifuged and 
serum samples were stored at-70 centigrade degree until 
assayed. All rats were sacrified by overdosing 
chloroform at the end of 4 week period. Total calcium 
and acid phosphate concentration in serum were 
determined by spectrophotometery using commercially 
available test kit (Ziestchem diagnostic, Tehran, Iran) 
(11, 18). Also osteocalcine concentration in serum was 
determined by enzyme immuno assay (DRG instrument 
GmbH, Germany) before and after treatment in all 
groups. 
 
Bone mineral densitometry (BMD) 
BMD were performed for evaluation of bone mass in 
lumbar vertebrae (19). The bone mineral content of 
lumbar vertebrae was measured by dual energy X ray 
absorptiometry (DEXA) using the Norlaand small 
subject (resolution 0.5 x 0.5 mm, speed 600 mm/s, Host 
scanner 3.2, 3.2 and 1.1). The bone mineral density 
(BMD) was expressed as a gram of mineral per unit area 
of bone (g/cm2). 
 
Statistical analysis 
In order to analysis biochemical markers and BMD 
measurement obtained in rats, one way analysis of 
variance (ANOVA), Duncan and Dunnett tests used to 
compare the means values between groups. A value of P 




Effect of methylprednisolone acetate and calcium 
supplementation on bone metabolic markers was 
evaluated. As the figure 1 shows, the concentration 
mean of serum acid phosphatase, a parameter of bone 
resorption, was increased significantly (P < 0.05) in 
group C in compared to A and B groups. This mean was 
increased significantly (P < 0.05) in group D in 
compared to A and B groups, but there was no 
significant difference between group C and D. 
The concentration mean of serum osteocalcine, a 
parameter of bone formation, in group C was decreased 
significantly (P < 0.05) in comparison to A and B 
groups. In group D, concentration mean of serum 
osteocalcine was increased significantly (P < 0.05) in 
comparison with group C but this difference in 
comparison with A and B groups were not significant 
(Figure 2). 
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Figure 1. Effect of 0.2 mg/kg of methylprednisolone acetate with or without 15mg/kg of supplemental calcium for 1 month on 
concentration of serum acid phosphatase of 24 male Sprague-Dawley rats. Values are mean + SE. Significant difference at P < 0.05. 
mpa = methylprednisolone acetate, mpa + ca = methylprednisolone acetate + calcium. 
 
 
The concentration mean of serum calcium in group 
D in comparison to other groups were not significant 
(Figure 3). Effect of methylprednisolone acetate and 
Calcium supplementation on BMD of lumbar vertebrae 
was evaluated too. The bone mineral density (g/Cm2) 
was decreased significantly (P< 0.05) in group C in 
compared to A and B groups but increased significantly 
in compared to the group D (Table 1) and (Figure 4). 
Table 1. Effect of 0.2 mg/kg of methylprednisolone 
acetate with or without 15 mg/kg of supplemental calcium for 
4weeks on bone mineral density (BMD) of 24 male Sprague-
Dawley rats. Values are means   SE. Significant difference 







Control 6 0.1362 5.94E-04 
Placebo 6 0.1320 1.19E-02 
MPA 6 0.1201 7.57E-03 
MPA+Ca 6 0.1272 5.46E-03 




Figure 2. Effect of 0.2 mg/kg of methylprednisolone acetate with or without 15 mg/kg of supplemental calcium for 4weeks on 
concentration of serum osteocalcin of 24 male Sprague-Dawley rats. Values are means SE. Significant difference at P<0.05. 
mpa=methylprednisolone acetate,  mpa+ca=methylprednisolone acetate+calcium. 
(tu/l) 
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Figure 3. Effect of 0.2 mg/kg of methylprednisolone acetate with or without 15mg/kg of supplemental calcium for 4weeks on 
concentration of serum calcium of 24 male Sprague-Dawley rats. Values are means   SE. Significant difference at P < 0.05.  
 
 
Figure 4. Bone mineral densities of  lumbar vertebra was measured by dual energy X ray absorptiometry (DEXA) in control (A), 
sham (B), Methylprednisolone acetate (C), Methylprednisolone and oral calcium supplementation (D)  groups. 
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Discussion 
 
Our results demonstrated that administration of low dose 
methylprednisolone acetate cause bone loss in lumbar 
vertebrae of experimental group compare to control 
group. It has been shown that the administration of 
glucocorticoids induces an increase in bone resorption, 
which results in a deacrease in bone mineral density in 
various bones in human (20, 21). Even in animal 
experiments, it has been demonstrated that the 
administration of glucocorticoids induces a decrease in 
the total body bone mineral content and results in a 
decrease in BMD (22-24 ). It seems, Glucocorticoids 
impede osteoblast formation by inhibiting the release of 
cellular growth factors (4). Glucocorticoids have 
profound effects on mineral metabolism and skeletal 
function and can lead to the development of short statue 
and osteoporosis (25). The most significant effect of 
glucocorticoids in bone is an inhibition of bone 
formation (11). This is because of decrease in the 
number of osteoblasts and their function. The decrease 
in cell number is secondary to a decrease in osteoblastic 
cell replication and differentiation and an increase in the 
apoptosis of mature osteoblasts (5). Anyway, In contrast 
to our study some long-term studies showed 
improvement or even normalization of bone mineral 
density after treatment with low dose of 
methylprednisolone acetate (26-28). Although the 
Medical Research Council and Nuffield Foundation 
trials in the mid-1950s and mid-1960s suggested a 
possible disease-modifying role for low dose of 
glucocorticoids (25). It is difficult to interpret the results 
of these trials, however, because of the heterogeneity of 
the patient groups, the long duration of disease at the 
start of studies, confounding by indication and multiple 
concomitant therapies (26). The results of present study 
also showed that administration of low dose 
methylprednisolone acetate cause significant increase in 
bone resorption marker (acid phosphatate) and a 
moderate decrease in bone formation marker 
(osteocalcin) of experimental group compared to control 
group. Our findings confirmed that the loss of bone 
mineral density resulted primary from decreased bone 
formation which reported by some researchers (2, 16). 
Also, According to our results, administration low dose 
of methylprednisolone acetate with 15 mg/kg of calcium 
supplementation cause significantly increase in bone 
mineral density and osteocalcin concentration and did 
not give rise to any significant reduction in acid 
phosphatase compared to low dose of 
methylprednisolone acetate alone. As intestinal calcium 
absorption is impaired by glucocorticoid therapy, it 
seems logical to increase calcium intake in the diet or by 
supplementation (29, 30), suggesting that calcium alone 
is not sufficient to prevent rapid bone loss in patients 
starting high-dose glucocorticoids (31). Although our 
finding were contrary to previous findings in humans 
and animals (27, 28), they are consistent with the data 
from recently studies that showed increased bone mass 
or prevention of bone loss by calcium administration 
synchronize with glucocorticoids treatment (29-32). 
There are multiple mechanisms underlying the 
regulation of bone remodeling, and these involve not 
only the osteoblastic and osteoclastic cell lineages but 
also other factors (33, 34). Decreased calcium intake, 
impaired intestinal absorption of calcium due to aging or 
disease, as well as vitamin D deficiency can result in 
secondary hyperparathyroidism (35). The active 
hormonal form, 1,25 dihydroxy vitamin D (calcitriol), is 
not only necessary for optimal intestinal absorption of 
calcium and phosphorus, but also exerts a tonic 
inhibitory effect on parathyroid hormone (PTH) 
synthesis, so that there are dual pathways that can lead 
to secondary hyperparathyroidism (34, 35). Vitamin D 
deficiency and secondary hyperparathyroidism can 
contribute not only to accelerated bone loss and 
increasing fragility of bone but also to neuromuscular 
impairment that can increase the risk of falls (36). 
Clinical trials involving individuals follows 
prednisolone exposure at high risk for calcium and 
vitamin D deficiency indicate that supplementation of 
both can reverse secondary hyperparathyroidism, 
increase bone mass, decrease bone resorption, decrease 
fracture rates, and even decrease the frequency of falling 
(37). Results from the present study support the 
hypothesis similar to observation made by osteoporosis 
is characterized by low bone mineral density and a 
deterioratic the micro architecture of bone that increase 
its susceptibility to fracture, calcium and vitamin 
supplementation likely to decrease bone complications. 
Thus Bone loss can be minimizing through proper 
nutrition, calcium and vitamin supplementation (30). In 
conclusion, the present data suggest that Calcium 
administration in optimal condition decreased effects 
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